On March 24, 2025, Cinven, an international private equity firm, finalized the sale of an indirect minority stake in SYNLAB, a prominent European medical diagnostic services provider, to Labcorp, a leading global laboratory services company based in the U.S. Labcorp acquired this stake through a newly established holding company, which also includes representation from Cinven and other co-investors.

SYNLAB operates in over 30 countries and employs more than 26,000 people, including 2,000 medical experts. In 2024, the company conducted approximately 600 million laboratory tests and generated revenues of around €2.62 billion. The partnership with Labcorp aims to explore future opportunities, including the introduction of Labcorp’s specialty tests in Europe, potential procurement collaborations, and advancements in clinical trials and personalized care.

Cinven focuses on building leading global and European companies across six sectors: Business Services, Consumer, Financial Services, Healthcare, Industrials, and Technology, Media, and Telecommunications (TMT). The firm emphasizes a responsible approach towards its portfolio companies and their stakeholders. Cinven operates offices in major cities including London, New York, and Frankfurt, and is regulated by the Guernsey Financial Services Commission and the Financial Conduct Authority.

Labcorp, listed on the NYSE, is recognized for its innovative laboratory services that assist healthcare providers and researchers in making informed decisions. With nearly 70,000 employees, Labcorp serves clients in about 100 countries and supports a significant portion of new drug approvals by the FDA. The company performs over 700 million tests annually, contributing to advancements in health and science.

SYNLAB is the leading provider of medical diagnostic services in Europe, offering a comprehensive range of reliable diagnostics to various stakeholders, including patients, healthcare professionals, and governments. The company is known for its innovative approach and strong market presence, reinforced by a successful acquisition strategy.

This press release includes forward-looking statements regarding the potential benefits of Labcorp’s investment in SYNLAB and the exploration of collaborative opportunities. However, these statements are subject to change due to various factors, including challenges related to employee retention and relations.

For more information about Cinven, visit their website or LinkedIn page, and for Labcorp and SYNLAB, additional details can be found on their respective websites.